GET DAILY SIGNALSDelcath Systems (DCTH) Analyst Targets Point to +28% Upside Potential
Key Takeaways
- The central target of $26 is the arithmetic mean of five verified analyst price targets reviewed for Delcath Systems, Inc. (DCTH), rounded from roughly $25.8.
- At the latest verified close of $20.27, reaching $26 implies a substantial move of roughly 28%.
- Individual analyst targets span a wide range from $21 to $32, with all five firms at Buy-equivalent ratings — a sign of agreement on direction but meaningful disagreement on magnitude.
- Strongest supports include accelerating HEPZATO/CHEMOSAT commercial momentum, raised 2026 revenue guidance, positive CHOPIN trial data, and label-expansion potential.
- Biggest risks include a very high valuation, a small-cap, single-product profile, quarter-to-quarter seasonality, and execution and clinical uncertainty.
- For more on this ticker, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
Analyst Price Targets and Consensus View
The $26 central target is calculated from five current, attributable analyst targets. The most bullish is H.C. Wainwright at $32 (Buy, maintained November 5, 2026), while the most cautious is Canaccord Genuity at $21 (Buy, reiterated November 3, 2026). In between, Craig-Hallum holds $24 (Buy, raised from $18 on August 7, 2026), BTIG's Marie Thibault holds $25 (Buy, raised from $21 on November 9, 2026), and Clear Street holds $27 (Buy). The simple average of these five figures is about $25.8, rounded to a clean $26 for this analysis. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Every reviewed firm rates the stock a Buy, which third-party aggregators commonly summarize as a "Strong Buy" analyst consensus. However, the $21-to-$32 spread is unusually wide for a small-cap name, reflecting genuine disagreement over how quickly HEPZATO adoption and future label expansions will convert into revenue and earnings. None of these figures is a guarantee, and the mean should not be read as an official published consensus.
Current Market Position and Path Toward the Target
As of the November 9, 2026 close, Delcath Systems, Inc. (DCTH) traded at $20.27, up sharply after third-quarter results, with a market capitalization near $703 million and a 52-week range of roughly $8.12 to $20.30. Reaching $26 would require about a 28% advance — a substantial, though not extreme, move for a volatile, high-growth medical-device stock.
The path would most likely depend on sustained HEPZATO KIT revenue growth in metastatic uveal melanoma, continued expansion of U.S. treatment centers, and progress toward broader indications such as liver-dominant metastatic colorectal cancer, where the company has cleared an investigational new drug application for a Phase 2 trial. Valuation is a wildcard: with trailing EPS near zero, the stock trades on forward revenue expectations rather than earnings, making sentiment and guidance revisions unusually important.
What Could Support a Move Toward the Target
- Commercial acceleration: Third-quarter 2026 revenue of $35.1 million beat estimates, and management raised full-year 2026 guidance to $115–$117 million, up from "at least $100 million."
- Clinical validation: Positive CHOPIN trial results and FOCUS subgroup data support HEPZATO use in combination and sequencing, which management says is extending duration of therapy.
- Label-expansion runway: FDA clearance of an IND for a Phase 2 colorectal cancer program and European guideline inclusion for CHEMOSAT broaden the addressable market.
- Financial footing: Roughly $95.9 million in cash and modest leverage provide room to fund trials and commercial expansion.
What Could Prevent the Target From Being Reached
- Rich valuation: With minimal trailing profitability, the stock is priced for sustained, execution-heavy growth; any disappointment can compress the multiple quickly.
- Concentration risk: Revenue depends heavily on a single product and, in the U.S., primarily one indication.
- Seasonality and lumpiness: Management has flagged fourth-quarter holiday-related step-downs in patient scheduling.
- Competition and clinical risk: Label-expansion trials may not succeed, and competing liver-directed therapies could pressure share.
Technical Levels and Market Structure
The stock broke to a fresh 52-week high around $20.30 on November 9, 2026, clearing a prior resistance zone near $18–$18.23. That former ceiling may now act as a support level on pullbacks, with the round-number $20 area as a nearby psychological marker. The 52-week low of $8.12 sits far below, underscoring the stock's wide trading range. A sustained hold above $20 would strengthen the technical case for a move toward the $24–$26 area, while a failure back below $18 would suggest the breakout lacked conviction.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms do not always disclose an exact timeframe. The most relevant near-term items are quarterly revenue and patient-start trends, any updates to guidance, analyst target revisions following results, and milestones in the colorectal cancer and other expansion programs. Investors should also watch treatment-center additions and any changes to the competitive or regulatory landscape. From what I see, monitoring these elements closely helps clarify the path forward.
Using AI Tools for Additional Perspective
I’ve been using Tickeron’s AI Daily Buy/Sell Signals to monitor DCTH alongside traditional analysis. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on market conditions, technical behavior, and data-driven insights. It serves as a useful complement to fundamental work by highlighting shifts that might otherwise require extensive manual review. In my view, it offers an efficient way to stay on top of daily changes without replacing deeper research.
Final Assessment
The $26 central target — the mean of five Buy-rated analyst targets spanning $21 to $32 — implies a substantial, roughly 28% move from the latest close of $20.27. The strongest arguments for such a move are accelerating HEPZATO revenue, raised guidance, positive clinical data, and a widening label-expansion pipeline. The principal obstacles are a demanding valuation, concentration in a single product and indication, seasonal revenue lumpiness, and execution risk. With unanimous Buy ratings but a very wide target range, the market is clearly optimistic about direction yet uncertain about magnitude. Whether DCTH reaches $26 will hinge on continued commercial execution and credible progress toward broader indications, which investors should monitor closely.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DCTH in downward trend: 10-day moving average moved below 50-day moving average on October 06, 2026
The 10-day moving average for DCTH crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
DCTH moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DCTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for DCTH entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DCTH's RSI Oscillator exited the oversold zone, 28 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 62 cases where DCTH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on DCTH as a result. In 76 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for DCTH just turned positive on November 04, 2026. Looking at past instances where DCTH's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
Following a +3.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where DCTH advanced for three days, in 198 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
DCTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. DCTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 61 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.276) is normal, around the industry mean (4.142). DCTH's P/E Ratio (1493.000) is considerably higher than the industry average of (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.757) is also within normal values, averaging (40.124).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement